GABA/(Creatine and Phosphocreatine) ratio
|
Basic information |
| Metabolite name | GABA/(Creatine and Phosphocreatine) ratio |
 | N/A |
 |
N/A |
 |
N/A |
| Synonyms | NA |
| No. of studies | 9 |
|
Basic information |
| Metabolite name | GABA/(Creatine and Phosphocreatine) ratio |
| N/A |
|
N/A |
|
N/A |
| Synonyms | NA |
| No. of studies | 9 |
|
Relationship between GABA/(Creatine and Phosphocreatine) ratio and depression (count: 9) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M1064 | Type1 | CUS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M1064 | Type2 | CUS + mirtazapine group vs. CUS group | Hippocampus | Wistar rat | Up |
| Study M240 | Type3 | citalopram post-treatment vs. pre-treatment | Occipital cortex | Human | Up |
| Study M294 | Type1 | CMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M294 | Type1 | CMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M337 | Type2 | citalopram-treated depression group 3 day treatment vs. baseline | Pregenual anterior cingulate cortex | Human | Down |
| Study M521 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M546 | Type1 | CUS offspring group vs. control offspring group, right hippocampus of male offspring | Hippocampus | Sprague-Dawley rat | Up |
| Study M656 | Type2 | low-dose yoga intervention group, scan 3 vs. scan 1 | Thalamus | Human | Up |
| Study M745 | Type3 | post vs. before ketamine treatment | Hippocampus | Human | Down |
| Study M785 | Type1 | MDD group vs. control group | Ventromedial prefrontal cortex | Human | Down |